Association of the rs17574 DPP4 Polymorphism with Premature Coronary Artery Disease in Diabetic Patients: Results from the Cohort of the GEA Mexican Study.
Gilberto Vargas-AlarconMaria Del Carmen González-SalazarAdrián Hernández-DiazCouderFausto Sánchez-MuñozJulián Ramírez BelloJosé-Manuel Rodríguez-PérezRosalinda Posadas-SánchezPublished in: Diagnostics (Basel, Switzerland) (2022)
Previously, it has been reported that hypoalphalipoproteinemia (HA) is associated with rs17574 DDP4 polymorphism. Considering that in diabetic patients, HA is often present and is a risk factor for premature coronary artery disease (pCAD), the study aimed to evaluate the association of this polymorphism with pCAD in diabetic individuals. We genotyped the rs17574 polymorphism in 405 pCAD patients with T2DM, 736 without T2DM, and 852 normoglycemic individuals without pCAD and T2DM as controls. Serum DPP4 concentration was available in 818 controls, 669 pCAD without T2DM, and 339 pCAD with T2DM. The rs17574 polymorphism was associated with lower risk of pCAD ( p additive = 0.007; p dominant = 0.003, p heterozygote = 0.003, p codominant1 = 0.003). In pCAD with T2DM patients, DPP4 levels were lower when compared with controls ( p < 0.001). In the whole sample, individuals with the rs17574 GG genotype have the lowest protein levels compared with AG and AA ( p = 0.039) carriers. However, when the same analysis was repeated separately in all groups, a significant difference was observed in the pCAD with T2DM patients; carriers of the GG genotype had the lowest protein levels compared with AG and AA ( p = 0.037) genotypes. Our results suggest that in diabetic patients, the rs17574 G &nbsp; DPP4 allele could be considered as a protective genetic marker for pCAD. DPP4 concentrations were lower in the diabetic pCAD patients, and the rs17574 GG carriers had the lowest protein levels.
Keyphrases